O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 2022 May 11. pii: 10.1007/s10549-022-06602.
PMID: 35545724